Ixazomib

Small molecule

Also known as MLN-9708

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Treatment of relapsed or refractory multiple myeloma
Product first approved 2017PMDA
EU
  • Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
Multiple Myeloma
NCT03562169 · University of Leeds
2017-03-20 – 2027-03 · Multiple Myeloma
What this study did
NCT03651128 · Celgene
2019-04-16 – 2026-04-13 · Multiple Myeloma
What this study did
NCT03720041 · University of Leeds
2020-08-04 – 2024-12 · Multiple Myeloma
What this study did
NCT03748953 · Millennium Pharmaceuticals, Inc.
2019-01-24 – 2023-12-06 · Multiple Myeloma
What this study did
Other / comorbidity
NCT02516423 · Alliance for Clinical Trials in Oncology
2016-11-29 – 2025-09-30 · Solitary Osseous Plasmacytoma
What this study did
NCT01659658 · Millennium Pharmaceuticals, Inc.
2012-12-26 – 2022-07-11 · Relapsed or Refractory Systemic Light Chain Amyloidosis
What this study did
Phase 2 (66)
Multiple Myeloma
NCT06744894 · Navy General Hospital, Beijing
2025-01-01 – 2030-01-01 · Multiple Myeloma
What this study did
NCT04998786 · Nantes University Hospital
2021-12-14 – 2030-01-01 · Multiple Myeloma at First Relapse
What this study did
NCT04790474 · Tel-Aviv Sourasky Medical Center
2021-03-25 – 2028-01-01 · Multiple Myeloma in Relapse, Refractory Multiple Myeloma
What this study did
NCT03376672 · Raija Silvennoinen
2018-05-31 – 2027-12-31 · Multiple Myeloma
What this study did
NCT03763162 · M.D. Anderson Cancer Center
2019-01-17 – 2027-10-30 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02253316 · Washington University School of Medicine
2015-01-20 – 2027-08-31 · Multiple Myeloma
What this study did
NCT03942224 · Emory University
2019-07-03 – 2026-07-31 · Plasma Cell Myeloma
What this study did
NCT04052880 · Larysa Sanchez
2019-10-24 – 2026-05-27 · Newly Diagnosed Multiple Myeloma
What this study did
NCT02619682 · Fred Hutchinson Cancer Center
2015-12-30 – 2025-10-24 · Plasma Cell Myeloma, Transplant-Related Carcinoma
What this study did
NCT03590652 · University of California, San Diego
2018-10-17 – 2025-07-02 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT01415882 · Mayo Clinic
2012-01-31 – 2025-04-30 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02461888 · University of Leeds
2015-12 – 2025-01-19 · Multiple Myeloma
What this study did
NCT02916771 · Dana-Farber Cancer Institute
2016-10 – 2025-01-08 · Smoldering Multiple Myeloma
What this study did
NCT03669445 · University Hospital, Toulouse
2018-12-31 – 2024-12 · Multiple Myeloma
What this study did
NCT03457142 · Roswell Park Cancer Institute
2018-09-11 – 2024-11-06 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02924272 · Takeda
2016-12-16 – 2024-07-03 · Multiple Myeloma, Lymphoma, Amyloidosis
What this study did
NCT03757221 · University Hospital, Caen
2019-02-07 – 2024-04-28 · Multiple Myeloma
What this study did
NCT03731832 · GWT-TUD GmbH
2018-09-20 – 2024-04-22 · Refractory Multiple Myeloma
What this study did
NCT04028115 · Thomas Lund
2019-10-24 – 2024-04-01 · Multiple Myeloma
What this study did
NCT02389517 · University of Chicago
2015-03-02 – 2024-01 · Plasma Cell Myeloma, Residual Disease
What this study did
NCT02412228 · John L. Reagan
2015-08 – 2023-11-09 · Multiple Myeloma
What this study did
NCT03733691 · Oncotherapeutics
2019-03-01 – 2023-10-19 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03439293 · Takeda
2018-03-13 – 2023-06-26 · Multiple Myeloma
What this study did
NCT02765854 · Emory University
2016-09-01 – 2023-05-23 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT01718743 · M.D. Anderson Cancer Center
2012-12-03 – 2023-04-12 · Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
What this study did
NCT03683277 · Intergroupe Francophone du Myelome
2019-11-03 – 2023-02-10 · Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genetic Condition
What this study did
NCT03012880 · Mayo Clinic
2017-04-20 – 2022-12-15 · Plasma Cell Myeloma
What this study did
NCT04119336 · Andrew Yee, MD
2020-02-14 – 2022-03-30 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT03746652 · Hellenic Society of Hematology
2018-12 – 2021-12 · Multiple Myeloma
What this study did
NCT03170882 · Millennium Pharmaceuticals, Inc.
2017-08-01 – 2021-11-26 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT03202628 · Mayo Clinic
2017-07-24 – 2021-04-13 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT03506360 · Mayo Clinic
2018-06-19 – 2020-12-10 · Recurrent Plasma Cell Myeloma
What this study did
NCT02547662 · Mayo Clinic
2015-12-24 – 2020-10-30 · Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma
What this study did
NCT02440464 · National Heart, Lung, and Blood Institute (NHLBI)
2015-08 – 2020-10-01 · Multiple Myeloma
What this study did
NCT02897830 · University Hospital, Toulouse
2016-08-05 – 2020-08-31 · Multiple Myeloma
What this study did
NCT02169791 · Northside Hospital, Inc.
2014-07-15 – 2020-07-28 · Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas, Multiple Myeloma
What this study did
NCT01936532 · Nantes University Hospital
2014-11-12 – 2020-06-04 · Newly Diagnosed Multiple Myeloma
What this study did
NCT02917941 · Takeda
2016-11-01 – 2019-08-31 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT02410694 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2015-04 – 2019-05-02 · Multiple Myeloma
What this study did
NCT02168101 · SCRI Development Innovations, LLC
2014-09 – 2019-02-01 · Multiple Myeloma
What this study did
NCT02499081 · University of Arkansas
2015-09 – 2018-05-17 · Multiple Myeloma
What this study did
NCT02578121 · University of Arkansas
2015-12 – 2017-01 · Multiple Myeloma
What this study did
NCT01660997 · National Cancer Institute (NCI)
2012-07-30 – 2014-03-11 · Multiple Myeloma
What this study did
Other / comorbidity
NCT04305691 · AIDS Malignancy Consortium
2023-11-07 – 2029-03-15 · Kaposi Sarcoma, Skin
What this study did
NCT02339922 · University of Washington
2016-05-19 – 2028-01-08 · Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT07881809 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-11-23 – 2027-11-05 · HIV (Human Immunodeficiency Virus)
What this study did
NCT03618537 · Memorial Sloan Kettering Cancer Center
2018-08-02 – 2027-08 · AL Amyloidosis
What this study did
Phase 1/2 (31)
Multiple Myeloma
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT04068597 · CellCentric Ltd.
2019-08-09 – 2027-03-31 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
What this study did
NCT04094961 · Omar Nadeem, MD
2019-09-18 – 2027-01-01 · Multiple Myeloma, Multiple Myeloma in Relapse
What this study did
NCT06050512 · Kathleen Dorritie
2023-10-02 – 2026-10 · Relapsed and Refractory Multiple Myeloma
What this study did
NCT03225417 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2017-05-16 – 2024-12-31 · Hematopoietic Stem Cell Transplantation, Multiple Myeloma
What this study did
NCT03732703 · Multiple Myeloma Research Consortium
2019-04-01 – 2024-12-31 · Relapsed Refractory Multiple Myeloma
What this study did
NCT02542657 · Joseph Tuscano
2015-10-22 – 2024-11-11 · Myeloma
What this study did
NCT01864018 · Mayo Clinic
2013-08-20 – 2023-09-09 · Amyloidosis, Plasma Cell Myeloma
What this study did
NCT02119468 · City of Hope Medical Center
2014-07-22 – 2022-12-01 · Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
What this study did
NCT02633059 · Mayo Clinic
2015-12-30 – 2022-11-01 · Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma
What this study did
NCT03856112 · National Cancer Institute (NCI)
2019-06-21 – 2021-12-31 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, t(11;14) Negative
What this study did
NCT02004275 · Alliance for Clinical Trials in Oncology
2014-02 – 2021-12-01 · Multiple Myeloma in Relapse
What this study did
NCT02477215 · Parameswaran Hari
2015-10-09 – 2020-09-17 · Multiple Myeloma
What this study did
NCT03492138 · Ajai Chari
2018-03-26 – 2020-01-14 · Multiple Myeloma
What this study did
NCT02057640 · Jason Valent
2014-05-22 – 2018-05-15 · Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
What this study did
NCT01217957 · Millennium Pharmaceuticals, Inc.
2010-11-22 – 2018-02-02 · Multiple Myeloma
What this study did
NCT01383928 · Millennium Pharmaceuticals, Inc.
2011-10-31 – 2017-11-27 · Multiple Myeloma
What this study did
NCT01335685 · Millennium Pharmaceuticals, Inc.
2011-06-27 – 2016-12-29 · Multiple Myeloma
What this study did
Other / comorbidity
NCT02420847 · M.D. Anderson Cancer Center
2015-07-03 – 2025-12-31 · Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
What this study did
NCT03817320 · Therapeutic Advances in Childhood Leukemia Consortium
2019-02-12 – 2025-06-30 · ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
What this study did
NCT02632396 · Emory University
2016-03-01 – 2024-08 · Mantle Cell Lymphoma
What this study did
NCT02481310 · Northwestern University
2015-10-28 – 2024-07 · Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
What this study did
NCT03323151 · PrECOG, LLC.
2018-08-13 – 2023-09-07 · Mantle-Cell Lymphoma
What this study did
NCT03236792 · Icahn School of Medicine at Mount Sinai
2017-06-12 – 2022-09-20 · AL Amyloidosis
What this study did
NCT02898259 · Brian Hill
2017-02-20 – 2022-06-06 · B Cell Lymphoma, Lymphoma
What this study did
NCT04079738 · H Scott Boswell
2019-09-20 – 2022-02-23 · AML, AML, Adult
What this study did
NCT02250300 · Mehdi Hamadani
2014-11-19 – 2020-10-06 · Allogeneic Hematopoietic Stem Cell Transplantation
What this study did
NCT03547700 · University of Michigan Rogel Cancer Center
2018-09-26 – 2020-08-27 · Lymphoma, T-Cell, Peripheral
What this study did
NCT02993094 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2016-11-21 – 2020-08-15 · Triple-Negative Breast Cancer
What this study did
NCT02946047 · Mayo Clinic
2017-03-20 – 2019-08-19 · Human Immunodeficiency Virus (HIV)
What this study did
NCT02447887 · Fox Chase Cancer Center
2015-08-14 – 2017-04-25 · Metastatic Renal Cell Carcinoma, RCC
What this study did
Phase 1 (33)
Multiple Myeloma
NCT02697383 · Memorial Sloan Kettering Cancer Center
2016-02 – 2024-05-08 · Multiple Myeloma, High Risk Smoldering Multiple Myeloma
What this study did
NCT03399539 · Mayo Clinic
2018-05-02 – 2024-02-23 · Recurrent Plasma Cell Myeloma, T(11;14)
What this study did
NCT03770260 · National Cancer Institute (NCI)
2020-02-10 – 2023-07-06 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT02831686 · Memorial Sloan Kettering Cancer Center
2016-07 – 2020-11-19 · Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT02504359 · OHSU Knight Cancer Institute
2015-07-20 – 2020-09-09 · Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
What this study did
NCT04272775 · Takeda
2012-06-05 – 2019-02-15 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT00932698 · Millennium Pharmaceuticals, Inc.
2009-10-12 – 2017-05-23 · Relapsed and Refractory Multiple Myeloma
What this study did
NCT01645930 · Millennium Pharmaceuticals, Inc.
2012-12-17 – 2017-04-11 · Multiple Myeloma
What this study did
NCT01830816 · Millennium Pharmaceuticals, Inc.
2013-09-16 – 2016-11-18 · Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT00963820 · Millennium Pharmaceuticals, Inc.
2009-10 – 2014-01 · Multiple Myeloma
What this study did
Other / comorbidity
NCT04847453 · National Cancer Institute (NCI)
2022-08-03 – 2028-06-30 · Recurrent AL Amyloidosis, Refractory AL Amyloidosis
What this study did
NCT03783416 · Queen Mary University of London
2020-06-15 – 2027-07-31 · Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
What this study did
NCT03283917 · M.D. Anderson Cancer Center
2018-02-07 – 2026-06-17 · Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
What this study did
NCT02921893 · Mayo Clinic
2016-10-31 – 2024-05-13 · Plasmacytoma, POEMS Syndrome
What this study did
NCT02942095 · M.D. Anderson Cancer Center
2017-03-06 – 2022-12-07 · Solid Tumors
What this study did
NCT03888534 · Millennium Pharmaceuticals, Inc.
2020-10-31 – 2022-08-30 · Precursor Cell Lymphoblastic Leukemia-lymphoma
What this study did
NCT02582359 · Massachusetts General Hospital
2016-01 – 2022-04 · Acute Myeloid Leukemia
What this study did
NCT03880123 · Matthew Ingham
2020-11 – 2020-11-24 · Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
What this study did
NCT02630030 · Emory University
2016-03-24 – 2020-09-03 · Glioblastoma
What this study did
NCT02042989 · M.D. Anderson Cancer Center
2014-06-27 – 2020-01-22 · Advanced Cancers
What this study did
NCT02228772 · Massachusetts General Hospital
2014-12 – 2019-11 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia
What this study did
NCT01318902 · Millennium Pharmaceuticals, Inc.
2011-04-27 – 2018-11-13 · Light-Chain Amyloidosis
What this study did
NCT02384746 · Dartmouth-Hitchcock Medical Center
2015-06-02 – 2018-06-10 · Breast Cancer
What this study did
NCT02578511 · Ehab L Atallah
2017-06-29 – 2018-02-13 · Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission
What this study did
NCT02176486 · Takeda
2014-06-09 – 2018-01-19 · Lupus Nephritis
What this study did
NCT02070458 · Case Comprehensive Cancer Center
2014-10-08 – 2017-08-15 · Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03422874 · Dartmouth-Hitchcock Medical Center
2016-08 – 2017-08-04 · Neoplasms, Lymphoma
What this study did
NCT01454076 · Millennium Pharmaceuticals, Inc.
2011-11-10 – 2016-06-16 · Nonhematologic Malignancies, Lymphoma
What this study did
NCT01887587 · Ehab L Atallah
2013-06 – 2016-02-29 · Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
What this study did
NCT01953783 · Millennium Pharmaceuticals, Inc.
2014-03-19 – 2016-02-09 · Advanced Solid Tumors, Lymphoma
What this study did
NCT01912222 · Millennium Pharmaceuticals, Inc.
2013-08 – 2015-03 · Advanced Solid Tumors, Hematologic Malignancies
What this study did
NCT00893464 · Millennium Pharmaceuticals, Inc.
2009-08 – 2014-10 · Lymphoma
What this study did
NCT00830869 · Millennium Pharmaceuticals, Inc.
2009-03-02 – 2012-04-20 · Advanced Non-hematologic Malignancies
What this study did
Phase 4 (5)
Multiple Myeloma
NCT05722405 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-01 – 2028-07-31 · Multiple Myeloma
What this study did
NCT04989140 · Peking Union Medical College Hospital
2021-07-26 – 2024-07-26 · Multiple Myeloma
What this study did
Early phase / not applicable (1)
Multiple Myeloma
NCT05477797 · RenJi Hospital
2023-02-16 – 2026-01-15 · Progression Free Survival, Overall Survival, Maintenance
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Multiple Myeloma
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05451771 · Columbia University
2022-10-26 – 2027-09 · AL Amyloidosis
What this study did
Phase 4 (1)
Multiple Myeloma
NCT04217967 · Peking Union Medical College Hospital
2019-09-24 – 2024-06-30 · Multiple Myeloma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ixazomib: this drugApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
TQB3602Phase 1Small moleculeProteasomeWeak signal
NCT04275583: Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.

Large race: only the 63 furthest-along competitors are listed; 104 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ixazomib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Myeloma, MultipleActive not recruiting
Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗
What to watch
2027 (8)
March 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple SclerosisRecruiting
Est. primary completion 2027-07-31 · NCT03783416 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2AL AmyloidosisActive not recruiting
Est. primary completion 2027-08 · NCT03618537 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-01 · NCT04790474 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2HIV (Human Immunodeficiency Virus)Not yet recruiting
Est. primary completion 2027-10-08 · NCT07881809 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10-30 · NCT03763162 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03376672 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT06744894 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1Recurrent AL Amyloidosis, Refractory AL AmyloidosisActive not recruiting
Est. primary completion 2028-06-30 · NCT04847453 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 2Kaposi Sarcoma, SkinActive not recruiting
Est. primary completion 2029-03-15 · NCT04305691 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-01-01 · NCT04998786 · CT.gov ↗
What to watch

See the full readout calendar ↗